Rating Change
Wedbush reiterated its Outperform rating on Bicara Therapeutics Inc. Common Stock (NASDAQ:BCAX) on August 12, 2026.
reiterateNASDAQ:BCAX
Wedbush Reiterates Outperform Rating on Bicara Therapeutics Inc. Common Stock (BCAX)
Wedbush reiterated its Outperform rating on Bicara Therapeutics Inc. Common Stock (NASDAQ:BCAX) on August 12, 2026.
At publication ·
What changed
Bicara Therapeutics Inc. Common Stock (NASDAQ:BCAX) · reiterate
- Firm
- Wedbush
- Rating
- Outperform to Outperform
- Price at event
- $24.63
- Market capitalization
- $1.0B
At a glance
Key takeaways
- Wedbush reiterated an Outperform rating on Bicara Therapeutics (BCAX) on August 12, 2026, with the stock trading at $24.63 and a market capitalization of $1.0 billion.
Market Context
Bicara Therapeutics Inc. Common Stock operates in the Healthcare sector. The stock currently trades at $24.63 with a market capitalization of $1.0B. The stock has gained 146.6% over the past 52 weeks.
Analyst coverage from Wedbush provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Bicara Therapeutics Inc. Common Stock.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Bicara Therapeutics Inc. Common Stock
Among the 10 most recent ratings: 5 Buy, 5 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Aug 12, 2026 | Morgan Stanley | Overweight | N/A |
| Aug 12, 2026 | Wedbush | Outperform | N/A |
| Aug 12, 2026 | Goldman Sachs | Neutral | N/A |
| Aug 12, 2026 | Mizuho | Neutral | N/A |
| Aug 12, 2026 | Wells Fargo | Equal-Weight | N/A |
Related Tools: Analyst Ratings Dashboard | View BCAX Stock Page
Frequently Asked Questions
What does the Outperform rating mean for BCAX?
A rating of Outperform from Wedbush reflects the analyst's outlook on Bicara Therapeutics Inc. Common Stock (NASDAQ:BCAX). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the BCAX forecast page.